Blog
RSS FeedPosted by Michael Wonder on 16 Sep 2021
Moderna announces Health Canada approves its COVID-19 vaccine
16 September 2021 - Moderna today announced Health Canada has approved the new drug submission for Spikevax (elasomeran mRNA vaccine), which ...
Posted by Michael Wonder on 15 Sep 2021
Health Canada approves Lumakras (sotorasib), the first and only targeted treatment for patients with KRAS G12C mutated locally advanced or metastatic non--small cell lung cancer
14 September 2021 - Once daily dosing option now available to address KRAS G12C, a driver of tumour growth found ...
Posted by Michael Wonder on 08 Sep 2021
Ultragenyx Canada announces Health Canada approval of a second indication for Crysvita (burosumab injection) for the treatment of tumour induced osteomalacia in adults
7 September 2021 - Ultragenyx Pharmaceutical today announced that Crysvita (burosumab Injection) has been approved by Health Canada for the treatment ...
Posted by Michael Wonder on 01 Sep 2021
Jazz Pharmaceuticals announces Health Canada approval of Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
31 August 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Sunosi (solriamfetol) for the treatment ...
Posted by Michael Wonder on 30 Aug 2021
Health Canada approves Myinfla (colchicine 0.5 mg extended release tablets), a new repurposed treatment for cardiovascular disease
27 August 2021 - A unique partnership between Pharmascience and the Montreal Heart Institute leads to the approval of Myinfla (colchicine ...
Posted by Michael Wonder on 29 Aug 2021
Moderna COVID-19 vaccine gets Health Canada approval for kids 12+
27 August 2021 - As the Delta variant rages through unvaccinated populations in Canada ahead of the back-to-school season, children ...
Posted by Michael Wonder on 25 Aug 2021
Vertex Pharma gets approval for cystic fibrosis drug for infants in Canada
25 August 2021 - Vertex Pharmaceuticals was given approval to market its drug ivacaftor that treats children as young as ...
Posted by Michael Wonder on 25 Aug 2021
Health Canada grants marketing authorisation for Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
24 August 2021 - Minjuvi is a new therapeutic option for eligible patients with DLBCL in Canada to address an ...
Posted by Michael Wonder on 24 Aug 2021
Optimising the data available via Health Canada’s clinical information portal
23 August 2021 - Through its Public Release of Clinical Information initiative, Health Canada has provided public access to a vast ...
Posted by Michael Wonder on 19 Aug 2021
Miravo Healthcare announces receipt of Health Canada Notice of Compliance for the paediatric use of Blexten
12 August 2021 - Blexten Label Expanded to Include Ages as Young as 4 Years Old. ...
Posted by Michael Wonder on 05 Aug 2021
Health Canada approves Arazlo lotion for acne vulgaris treatment
4 August 2021 - Bausch Health said that Health Canada has approved the Notice of Compliance for Arazlo ( tazarotene) ...
Posted by Michael Wonder on 02 Aug 2021
GSK receives authorization under Health Canada's Interim Order for sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
30 July 2021 - GSK announced today that Health Canada has granted an Interim Order Authorisation for sotrovimab for Injection (sotrovimab, ...
Posted by Michael Wonder on 02 Aug 2021
Benlysta now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
30 July 2021 - Benlysta (belimumab) has been approved in Canada for the treatment of active lupus nephritis in adult ...
Posted by Michael Wonder on 26 Jul 2021
BeiGene announces approval in Canada of Brukinsa (zanubrutinib) for the treatment of patients with mantle cell lymphoma
26 July 2021 - Second approval for BTK inhibitor Brukinsa in Canada. ...
Posted by Michael Wonder on 21 Jul 2021
New treatment authorised and available for Canadians with HER2 positive breast cancer
20 July 2021 - Phesgo, a fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection combines two treatments into ...